Skip to content


Developing pancreatic cancer research across Europe

The PCE Board members, in particular Dr Nuria Malats, are glad to announce the launch of the PCE short-term scientific stay award (ECI)!

The grant will allow Early Career Investigators to go to an institution or laboratory in another European country (from the EU) to foster international collaboration, learn new techniques and access technology unavailable in their own countries.

The applications for this grant are now opened until 31 May 2019. Please send your application to

The result of the grant will be unveiled during European Pancreas Club Congress in Bergen in June 2019. Do not hesitate to write directly to the Secretariat for any further information regarding the grant (

The Research Work Stream had been created following the will to contribute to the debate on what changes are needed to improve research on this cancer, after the General assembly meeting. The Research Work Stream promotes policies & research programmes that can advance medical science on pancreatic cancer.

The main goal of the Work Stream is to bring together researchers, clinicians, private domain, patients, and policy makers to identify/discuss on priorities in Pancreatic cancer research. We aim also to make EU institutions aware and committed to the issues relating to pancreatic cancer.

On Wednesday 12th April 2017, EUPancreas (COST Action) and Pancreatic Cancer Europe gathered key pancreatic cancer research experts, clinicians, private domain representatives, health policy makers, and patient advocates during a meeting in Brussels.

This very first “Multistakeholder Brainstorming meeting” was organised around the belief that researchers, clinicians, patient representatives, pharma and biotech companies, policy makers, European institutions, in a joint collaboration, have a fundamental role to play in pancreatic cancer research.

Following an initiative from our Board Member, Dr. Nuria Malats, the exchanges aimed to propose concrete solutions in favour of research on pancreatic cancer in Europe. Indeed, we think it is time for EU institutions, Members of the European Parliament and national ministries to trigger real change in research, to further improve patient outcomes and survival rates.

The result of the exchanges are precise priorities for research on pancreatic cancer, detailed in the meeting report, that will be sent to European policy makers.

Please find here the meeting report.

Pathology of the exocrine pancreas – of mice and men

National Center for Tumor Diseases (NCT) and European Pancreas Center (EPZ) biobanks in Heidelberg

Interactions in Complex Disease Analysis

Access to Personalised Medicine for PDAC-patients

EUPancreas in the 19TH European Health Forum Gastein (EHFG) – 30 September 2016 – Gastein


Dr. Núria Malats

Dr. Núria Malats is currently the head of the Genetic and Molecular Epidemiology Group at the Spanish National Cancer Research Centre (CNIO), Madrid, Spain. She has a broad expertise in these fields of research by focusing mainly on bladder and pancreas cancer. She coordinates several large national and international studies integrating different levels of information, including omics data, in both disease development and progression. She has over 250 publications and is external reviewer of national and international funding agencies and first rank scientific journals. Dr. Malats chaired the EUPancreas COST Action (BM1204), is a board member of the International Pancreatic Cancer Case Control Consortium (PanC4), and the chair of the Research Work Stream of Pancreatic Cancer Europe (PCE) multistakeholder platform.

Pancreatic Cancer Europe

Related Projects and Activities

The importance of pancreatic cancer’s early detection

Pancreatic cancer is not one of the most frequently diagnosed cancers, but it is one of the most lethal due to its early local extension and metastatic behaviour. Some of the reasons for this high fatality rate are the aggressiveness of the disease, its late diagnosis, especially since symptoms are unspecific and appear rather late, and the available limited therapeutic options.

PancreOS – Pancreatic cancer overall survival registry in Europe, 2015

In 2015, the Spanish Cooperative Group TTD – Tratamiento de los Tumores Digestivos (Digestive Tract Tumors Treatment) started to execute a pilot registry called PancreOS, aiming at collecting a comprehensive set of prospective data from pancreatic cancer patients at any stage of the disease. The pilot project led in Spain has been a good example of what can be done at EU level for pancreatic cancer registries. PCE endorsed the initiative and continues to expand it to more countries all across Europe.

PancreOS – Pancreatic cancer overall survival registry in Europe, 2021

Pancreatic cancer is the only cancer with mortality on the rise in both sexes. The late diagnosis of pancreatic cancer is notably due to the lack of identified biomarkers, genes or imaging modalities. Improved survival rates depend on improved knowledge of the disease, increasing the ability to diagnose it earlier. If advances in pancreatic cancer research are to be made and the commitments of Member States to effective cancer control fulfilled, then registries on pancreatic cancer are a prerequisite.